AIM Financials

Income Statement
MetricQ3 2026Q2 2026Q1 2026Q4 2025Q3 2025
Revenue
22.0K
-15.4%
26.0K
+18.2%
22.0K
+4.8%
21.0K
-19.2%
26.0K
Cost of Revenue
7.0K
+40.0%
5.0K
+25.0%
4.0K
-90.0%
40.0K
-41.2%
68.0K
Gross Profit
15.0K
-28.6%
21.0K
+16.7%
18.0K
+194.7%
-19000
+54.8%
-42000
Operating Expenses
3.0M
-15.9%
3.5M
+57.5%
2.2M
-23.5%
2.9M
+22.0%
2.4M
R&D
846.0K
+43.6%
589.0K
+22.2%
482.0K
-54.7%
1.1M
+75.1%
607.0K
SG&A
2.1M
-27.8%
2.9M
+67.1%
1.8M
-5.8%
1.9M
+4.0%
1.8M
Operating Income
-2957000
+15.8%
-3513000
-57.8%
-2226000
+24.6%
-2952000
-20.6%
-2447000
EBITDA
-2676000
+10.4%
-2985000
-36.7%
-2183000
+25.0%
-2909000
-28.4%
-2265000
Net Income
-3143000
+17.0%
-3788000
-25.3%
-3023000
+27.6%
-4175000
-27.1%
-3284000
EPS (Basic)
$-0.10
+76.7%
$-0.43
+37.7%
$-0.69
—
$-1.57
EPS (Diluted)
$-0.10
+76.7%
$-0.43
+37.7%
$-0.69
—
$-1.57
Shares (Diluted)
32.5M
+89.8%
17.1M
+293.4%
4.4M
—
2.1M
AIM ImmunoTech (AIM) — Financials